PMID- 29212837
OWN - NLM
STAT- MEDLINE
DCOM- 20180806
LR  - 20221115
IS  - 1600-0617 (Electronic)
IS  - 0905-9180 (Print)
IS  - 0905-9180 (Linking)
VI  - 26
IP  - 146
DP  - 2017 Dec 31
TI  - Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
LID - 10.1183/16000617.0057-2017 [doi]
LID - 170057
AB  - Pirfenidone is one of two approved therapies for the treatment of idiopathic 
      pulmonary fibrosis (IPF). Randomised controlled clinical trials and subsequent 
      post hoc analyses have demonstrated that pirfenidone reduces lung function 
      decline, decreases mortality and improves progression-free survival. Long-term 
      extension trials, registries and real-world studies have also shown similar 
      treatment effects with pirfenidone. However, for patients with IPF to obtain the 
      maximum benefits of pirfenidone treatment, the potential adverse events (AEs) 
      associated with pirfenidone need to be managed. This review highlights the 
      well-known and established safety profile of pirfenidone based on randomised 
      controlled clinical trials and real-world data. Key strategies for preventing and 
      managing the most common pirfenidone-related AEs are described, with the goal of 
      maximising adherence to pirfenidone with minimal AEs.
CI  - Copyright (c)ERS 2017.
FAU - Lancaster, Lisa H
AU  - Lancaster LH
AD  - Vanderbilt University Medical Center, Nashville, TN, USA 
      lisa.lancaster@vanderbilt.edu.
FAU - de Andrade, Joao A
AU  - de Andrade JA
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Zibrak, Joseph D
AU  - Zibrak JD
AD  - Beth Israel Deaconess Medical Center, Boston, MA, USA.
FAU - Padilla, Maria L
AU  - Padilla ML
AD  - Mount Sinai - National Jewish Health Respiratory Institute, New York, NY, USA.
FAU - Albera, Carlo
AU  - Albera C
AD  - University of Turin, Turin, Italy.
FAU - Nathan, Steven D
AU  - Nathan SD
AD  - Inova Fairfax Hospital, Falls Church, VA, USA.
FAU - Wijsenbeek, Marlies S
AU  - Wijsenbeek MS
AD  - Erasmus University Medical Centre Rotterdam, Rotterdam, The Netherlands.
FAU - Stauffer, John L
AU  - Stauffer JL
AD  - Genentech, Inc., South San Francisco, CA, USA.
FAU - Kirchgaessler, Klaus-Uwe
AU  - Kirchgaessler KU
AD  - F. Hoffmann-La Roche Ltd, Basel, Switzerland.
FAU - Costabel, Ulrich
AU  - Costabel U
AD  - Ruhrlandklinik, University of Duisberg-Essen, Essen, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171206
PL  - England
TA  - Eur Respir Rev
JT  - European respiratory review : an official journal of the European Respiratory 
      Society
JID - 9111391
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pyridones)
RN  - D7NLD2JX7U (pirfenidone)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use
MH  - Disease-Free Survival
MH  - Humans
MH  - Idiopathic Pulmonary Fibrosis/*drug therapy/mortality/pathology/physiopathology
MH  - Lung/*drug effects/pathology/physiopathology
MH  - Medication Adherence
MH  - Pyridones/adverse effects/*therapeutic use
MH  - Recovery of Function
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC9488585
COIS- Conflict of interest: Disclosures can be found alongside this article at 
      err.ersjournals.com
EDAT- 2017/12/08 06:00
MHDA- 2018/08/07 06:00
PMCR- 2017/12/06
CRDT- 2017/12/08 06:00
PHST- 2017/05/12 00:00 [received]
PHST- 2017/09/07 00:00 [accepted]
PHST- 2017/12/08 06:00 [entrez]
PHST- 2017/12/08 06:00 [pubmed]
PHST- 2018/08/07 06:00 [medline]
PHST- 2017/12/06 00:00 [pmc-release]
AID - 26/146/170057 [pii]
AID - ERR-0057-2017 [pii]
AID - 10.1183/16000617.0057-2017 [doi]
PST - epublish
SO  - Eur Respir Rev. 2017 Dec 6;26(146):170057. doi: 10.1183/16000617.0057-2017. Print 
      2017 Dec 31.